Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Related to this article
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
Advertisement
Advertisement
Trending on OncLive
1
Dr Forde on ctDNA and MRD Testing in NSCLC
2
Dr Forde on Perioperative Osimertinib and Biomarker Testing in Resectable EGFR-Mutated NSCLC
3
Cross Currents: ADCs After EGFR TKI Progression in EGFR-Mutated NSCLC
4
Dr Calais on Sequencing PSMA-Targeted Therapy With PARP Inhibitors and Chemotherapy in Prostate Cancer
5